| Autor: |
Pogoda, Katarzyna, Jagiełło-Gruszfeld, Agnieszka, Kunkiel, Michał, Niwińska, Anna, Nowecki, Zbigniew |
| Předmět: |
|
| Zdroj: |
Oncology in Clinical Practice (2450-1654); 2023, Vol. 19 Issue 6, p433-443, 11p |
| Abstrakt: |
Triple-negative is the rarest breast cancer biological subtype of breast cancer, but has the most aggressive course. The resuls of chemotherapy, especially in advanced disease, are unsatisfactory. Numerous clinical trials have been conducted, that resulted in registrations of new drugs decreasing the risk of recurrence and improving the outcome of patients with metastatic disease. The article summarizes the data on modern therapies registered in recent years. The role of pembrolizumab in perioperative treatment in the early stage was indicated, as well as the importance of olaparib in BRCA mutation carriers. Additionally, in patients with metastatic the indication for immunotherapy (pembrolizumab and atezolizumab), sacituzumab govitecan and PARP inhibitors (olaparib and talazoparib) in BRCA mutation carriers were highlighted. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
